Treating Early-Stage Node-Negative Triple-Negative Breast Cancer

Opinion
Video

Ruth M. O'Regan, MD, and Anna Weiss, MD, join the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of early-stage node-negative triple-negative breast cancer (TNBC).

Recent Videos
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Related Content
Pelareorep plus paclitaxel improved the overall response rate vs paclitaxel monotherapy among patients in the phase 2 BRACELET-1 study.

Pelareorep Combo Yields Survival Benefit in HR+/HER2– Breast Cancer

Russ Conroy
September 19th 2024
Article

Pelareorep plus paclitaxel improved the overall response rate vs paclitaxel monotherapy among patients in the phase 2 BRACELET-1 study.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.

1-Year Trastuzumab Regimen Yields DFS in ERBB2+ Breast Cancer

Harrison Widelitz
September 18th 2024
Article

DFS was improved with 1-year trastuzumab in patients with ERBB2-positive breast cancer enrolled in the SOLD trial.

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Finding a Place for Exercise Oncology in the Treatment of Breast Cancer

Neil M. Iyengar, MD
May 20th 2024
Podcast

Neil M. Iyengar, MD, spoke about the potential impact of exercise on patient-reported outcomes in cancer and achieving work-life balance.

Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.

Ribociclib Combo Yields Extended iDFS Benefit in HR+/HER2– Breast Cancer

Russ Conroy
September 16th 2024
Article

Data from NATALEE continue to support the addition of ribociclib to adjuvant nonsteroidal aromatase inhibitors in HR-positive, HER2-negative breast cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

Breastfeeding Is Feasible Amid Endocrine Therapy Break in HR+ Breast Cancer

Ariana Pelosci
September 16th 2024
Article

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.